Narrative review: Statin-related myopathy

Annals of Internal Medicine

Volumn 150, Issue 12, 2009, Pages 858-868

  Joy, Tisha R ^a,b   Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NEFAZODONE; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; VERAPAMIL;

CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; GENETIC RISK; HUMAN; LIFE SUSTAINING TREATMENT; LOW DRUG DOSE; MORBIDITY; MYALGIA; MYOPATHY; MYOSITIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 67249111853     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-12-200906160-00009     Document Type: Review

References (87)

1. Mitka M. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA. 2003;290:2243-2245 [PMID: 14600168] (Pubitemid 37430551)
2. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572 [PMID: 12142128]
3. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9:389-396 [PMID: 18001622] (Pubitemid 350104239)
4. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C-94C. [PMID: 16581336]
5. Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med. 1968;279:856-858 [PMID: 5677720]
6. Smals AG, Beex LV, Kloppenborg PW. Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy [Letter]. N Engl J Med. 1977;296:942. [PMID: 846520] (Pubitemid 8074100)
7. Johnson TE, Zhang X, Shi S, Umbenhauer DR. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol. 2005;208:210-221 [PMID: 16239165] (Pubitemid 41457224)
8. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145:91-98 [PMID: 9221828] (Pubitemid 27294774)
9. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237 [PMID: 17560286] (Pubitemid 46856819)
10. Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-68 [PMID: 16003294] (Pubitemid 40956932)
11. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229 [PMID: 8463436] (Pubitemid 23129500)
12. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87:8931-8934 [PMID: 2247468] (Pubitemid 120007623)
13. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 1993;46:1055-1057 [PMID: 8254097] (Pubitemid 23349243)
14. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77:851-854 [PMID: 8623738] (Pubitemid 26143495)
15. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57:62-66 [PMID: 7828383]
16. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1994;46:313-317 [PMID: 7957515] (Pubitemid 24167378)
17. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61:889-892 [PMID: 15210526] (Pubitemid 38747328)
18. Tomasetti M, Alleva R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors. 1999;9:231-240 [PMID: 10416035] (Pubitemid 29289001)
19. Bleske BE, Willis RA, Anthony M, Casselberry N, Datwani M, Uhley VE, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J. 2001;142:E2. [PMID: 11479481]
20. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94:1306-1310 [PMID: 15541254] (Pubitemid 39469957)
21. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl). 1993;193:263-273 [PMID: 8278673] (Pubitemid 23319581)
22. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol. 2004;200:237-250 [PMID: 15504460] (Pubitemid 39422423)
23. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J. 2007;21:4087-4094 [PMID: 17634390] (Pubitemid 350232365)
24. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 2005;57:1475-1484 [PMID: 16259781] (Pubitemid 350066991)
25. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585 [PMID: 12353945]
26. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62:1709-1712 [PMID: 16286544] (Pubitemid 41626667)
27. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210:94-102. [PMID: 16799920] (Pubitemid 44288185)
28. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol. 2006;97:6C-26C. [PMID: 16581330]
29. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C-60C. [PMID: 16581329]
30. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-2797 [PMID: 17159064] (Pubitemid 46018281)
31. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690 [PMID: 12672737] (Pubitemid 37430274)
32. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C-43C. [PMID: 16581327]
33. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414 [PMID: 16453090] (Pubitemid 43228152)
34. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-1770 [PMID: 17919557] (Pubitemid 47494553)
35. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253-260 [PMID: 17472818] (Pubitemid 46661859)
36. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178:576-584 [PMID: 18299547]
37. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [Letter]. N Engl J Med. 2002;346:539-540 [PMID: 11844864] (Pubitemid 34441756)
38. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35. [PMID: 16490577] (Pubitemid 43254987)
39. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671-2676 [PMID: 16344427] (Pubitemid 41785067)
40. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97:44C-51C. [PMID: 16581328]
41. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525-528 [PMID: 15025753] (Pubitemid 38519660)
42. U.S. Food and Drug Administration. Zocor (Simvastatin) Prescribing Information. Accessed at www.fda.gov/cder/foi/label/2008/019766s076lbl.pdf on 20 December 2008.
43. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci. 2008;35:8-21. [PMID: 18380273]
44. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581 [PMID: 17178259] (Pubitemid 44908269)
45. Ray GM. Antiretroviral and statin drug-drug interactions. Cardiol Rev. 2009;17:44-47 [PMID: 19092370]
46. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al; NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577 [PMID: 11873000]
47. U.S. Food and Drug Administration. New Drug Application (for Lovastatin). Accessed at www.fda.gov/cder/foi/appletter/2002/19643slr071ltr.pdf on 20 December 2008.
48. U.S. Food and Drug Administration. Lipitor. Accessed at www.fda.gov/medwatch/safety/2007/Sep-PI/Lipitor-PI.pdf on 20 December 2008.
49. U.S. Food and Drug Administration. Crestor. Accessed at www.fda.gov/medwatch/SAFETY/2005/Mar-PI/Crestor-PI.pdf on 20 December 2008.
50. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340-345 [PMID: 11372002] (Pubitemid 32477075)
51. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73:538-544 [PMID: 12811363] (Pubitemid 37249124)
52. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463 [PMID: 15116058] (Pubitemid 38534566)
53. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122 [PMID: 15619408] (Pubitemid 40051126)
54. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther. 2007;81:679-684 [PMID: 17301736] (Pubitemid 46625102)
55. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359:789-799 [PMID: 18650507]
56. U.S. Food and Drug Administration. Information on Simvastatin/Amiodarone. Accessed at www.fda.gov/cder/drug/infopage/simvastatin-amiodarone/default.htm on 20 December 2008.
57. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005;78:551-558 [PMID: 16321621]
58. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics. 2007;17:695-707. [PMID: 17700359] (Pubitemid 47263065)
59. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79:532-539 [PMID: 16765141] (Pubitemid 43833450)
60. Mulder AB, van Lijf HJ, Bon MA, van den Bergh FA, Touw DJ, Neef C, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 2001;70:546-551 [PMID: 11753271] (Pubitemid 34008412)
61. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007;55:310-317 [PMID: 17289397] (Pubitemid 46518161)
62. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7. [PMID: 17376224] (Pubitemid 46482316)
63. Ruaño G, Thompson PD, Windemuth A, Seip RL, Dande A, Sorokin A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007;36:329-335 [PMID: 17600820] (Pubitemid 47326011)
64. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153-162 [PMID: 16671104] (Pubitemid 44167798)
65. Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med. 2000;160:1199-1203 [PMID: 10789615] (Pubitemid 30227032)
66. Klein JP, Fiedler U, Appel H, Quante A, Jockers-Scherübl MC. Massive creatine kinase elevations with quetiapine: report of two cases [Letter]. Pharmacopsychiatry. 2006;39:39-40. [PMID: 16453254] (Pubitemid 43235450)
67. Brown Jr. RH, Amato AA, Mendell JR. Muscular dystrophies and other muscle diseases. In: Fauci AS, Kasper DL, Longo DL, et al, eds. Harrison's Principles of Internal Medicine (e-Book). 17th ed. New York: McGraw-Hill; 2008.
68. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008;101:490-496 [PMID: 18312764] (Pubitemid 351199443)
69. Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with non-statin lipid-lowering therapies. Clin Ther. 2006;28:933-942 [PMID: 16860175] (Pubitemid 44062693)
70. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J. 2002;144:674-677 [PMID: 12360164]
71. Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005;8:197-199 [PMID: 16230873]
72. Ferrer-García JC, Pérez-Silvestre J, Martínez-Mir I, Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol. 2006;43:75-78 [PMID: 17143784] (Pubitemid 44875441)
73. Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42:341-346 [PMID: 18285559]
74. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007;100:554-555 [PMID: 17659946]
75. Mackie BD, Satija S, Nell C, Miller J 3rd, Sperling LS. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol. 2007;99:291. [PMID: 17223437] (Pubitemid 46072773)
76. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23:2183-2192 [PMID: 17692154] (Pubitemid 350246604)
77. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract. 2007;13:11-16 [PMID: 17360295]
78. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409-1412 [PMID: 17493470] (Pubitemid 46686635)
79. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400-1403 [PMID: 17950797]
80. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160 [PMID: 12860216] (Pubitemid 36835963)
81. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol. 2006;26:2433-2438 [PMID: 16973966] (Pubitemid 44607462)
82. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al; Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741 [PMID: 12713767]
83. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al; Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-1097 [PMID: 12423709] (Pubitemid 35335597)
84. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99:257-273 [PMID: 16553100]
85. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415 [PMID: 12719279]
86. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20:309-318 [PMID: 15322437] (Pubitemid 39108843)
87. Landstad BJ, Schüldt K, Ekholm J, Broman L, Bergroth A. Women at work despite ill health: diagnoses and pain before and after personnel support. A prospective study of hospital cleaners/home-help personnel with comparison groups. J Rehabil Med. 2001;33:216-224 [PMID: 11585153] (Pubitemid 32834148)